Bcl-2 Inhibitor

YCW-E11 is a Bcl-2, and Mcl-1 inhibitor with K_i values of 0.83 and 0.33 μM, respectively. YCW-E11 induces cell apoptosis through the mitochondrial pathway and exhibits antitumor activity. YCW-E11 can be utilized in cancer research.

3-Methylxanthine-d₃ is deuterated labeled 3-Methylxanthine (HY-50723). 3-Methylxanthine is a blood-brain barrier-permeable cyclic GMP phosphodiesterase inhibitor, with an IC₅₀ of 920 μM against guinea pig cyclic GMP phosphodiesterase. 3-Methylxanthine relaxes the spontaneous tension of isolated guinea pig tracheal smooth muscle preparations. Through a DRD1-dependent pathway, 3-Methylxanthine upregulates the expression of γH2AX and activated caspase-3, downregulates the expression of Bcl-2, and enhances Cisplatin-induced apoptosis (apoptosis) in ovarian cancer cells both in vitro and in vivo. 3-Methylxanthine induces clonic convulsions in the central nervous system. 3-Methylxanthine is the major metabolite of Theophylline (HY-B0809). 3-Methylxanthine can be used in studies related to ovarian cancer and neurotoxic convulsions.

Lig4-4 is an orally active and selective TREK-1 inhibitor, with an IC₅₀ of 2.06 μM in rats. Lig4-4 improves neuronal viability, reduces cell apoptosis by upregulating cleaved-caspase-3 and downregulating Bcl-2, and decreases infarct volume. Lig4-4 exerts a neuroprotective effect against cerebral ischemia injury. Lig4-4 can be used in studies related to cerebral ischemia.